The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Open accessPublished version of a preprint
Abstract
BACKGROUND: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa. METHODS: viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart. Serum samples obtained from 25 participants after the second dose were tested by pseudovirus and live-virus neutralization assays against the original D614G virus and the B.1.351 variant. The primary end points were safety and efficacy of the vaccine against laboratory-confirmed symptomatic coronavirus 2019 illness (Covid-19) more than 14 days after the second dose. RESULTS: Between June 24 and November 9, 2020, we enrolled 2026 HIV-negative adults (median age, 30 years); 1010 and 1011 participants received at least one dose of placebo or vaccine, respectively. Both the pseudovirus and the live-virus neutralization assays showed greater resistance to the B.1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipients. In the primary end-point analysis, mild-to-moderate Covid-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9% (95% confidence interval [CI], -49.9 to 59.8). Among the 42 participants with Covid-19, 39 cases (95.1% of 41 with sequencing data) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, -76.8 to 54.8). The incidence of serious adverse events was balanced between the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Geometric mean titers dropped from 297 against the original virus to 85 against the RBD-only mutant and 74 against the B.1.351 variant.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 1467 seronegative participants (750 assigned to the vaccine and 717 to placebo) were eligible for the primary efficacy analysis; reasons for exclusion are listed in Figure 1.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Participants
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“In a post hoc analysis of vaccine efficacy at more than 14 days after a single injection through October 31, 2020, as a proxy for infection by a non–B.1.351 variant (Fig. S1),15,27 the overall attack rate of mild-to-moderate Covid-19 at least 14 days after the first injection was 1.3% in placebo recipients and 0.3% in vaccine recipients; vaccine efficacy was 75.4% (95% CI, 8.7 to 95.5) (Table S8).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Vaccine Efficacy
What the sources say
- Not checked yetcites [15] Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. December 22, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1). preprint.
- Not checked yetcites [27] National Institute for Communicable Diseases. Dominance of the SARS-CoV-2 501Y.V2 lineage in Gauteng. January 28, 2021 (https://www.nicd.ac.za/wp-content/uploads/2021/01/Dominance-of-the-SARS-CoV-2-501Y.V2-lineage-in-Gauteng-South-Africa-1.pdf.) preprint.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both the pseudovirus and the live-virus neutralization assays showed greater resistance to the B.1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipients.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Results
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Live-virus assay showed lower neutralization overall, relative to pseudovirus assay (Figure 2C).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of serious adverse events was balanced between the vaccine and placebo groups.”
- Also stated in: § Safety · plain
“The incidence of adverse events and serious adverse events was similar among vaccine and placebo recipients (Tables S3 and S4).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Results
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Safety · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 87 spike-specific antigens identified by the sequencing, 75 remained unaffected by the B.1.351 mutations.”
- Also stated in: § Discussion · plain
“In a post hoc analysis reported here, we found that in spike-specific T cells that expanded after vaccination with ChAdOx1 nCoV-19, the majority of antigens and epitopes remained intact in recognition of the B.1.351 variant.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall vaccine efficacy for Covid-19 of any degree of severity more than 14 days after the first dose was 33.5% (95% CI, −13.4 to 61.7).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Vaccine Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a secondary-outcome analysis, efficacy against B.1.351 was not evident (vaccine efficacy, 10.4%; 95% CI, −76.8 to 54.8) (Table 2).”
- Also stated in: § Results · plain
“Among the 42 participants with Covid-19, 39 cases (92.9%) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, −76.8 to 54.8).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Vaccine Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 42 participants with Covid-19, 39 cases (92.9%) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, −76.8 to 54.8).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 17
- Probably not a substantial claim. 10
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the primary end-point analysis, mild-to-moderate Covid-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9% (95% confidence interval [CI], −49.9 to 59.8).”
- Also stated in: § Vaccine Efficacy · plain
“The incidence of confirmed mild-to-moderate Covid-19 more than 14 days after the second dose among previously seronegative participants was 93.6 per 1000 person-years in the placebo group and 73.1 per 1000 person-years in the vaccine group; vaccine efficacy was 21.9% (95% CI, −49.9 to 59.8) (Table 2 and Figure 3).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Vaccine Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 42 cases of Covid-19 were graded as mild (15 vaccine recipients and 17 placebo recipients) or moderate (4 vaccine recipients and 6 placebo recipients); there were no cases of severe disease or hospitalization in either group.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Vaccine Efficacy
Strength:plain· not yet calibratedn = 42Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Between June 24 and November 9, 2020, we enrolled 2026 HIV-negative adults (median age, 30 years); 1010 and 1011 participants received at least one dose of placebo or vaccine, respectively.”
- Also stated in: § Participants · plain
“We screened 3022 persons across seven sites and enrolled 2026 HIV-negative persons in the trial between June 24 and November 9, 2020.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Results
Strength:plain· not yet calibratedn = 2,026Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Participants · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Humoral response to the ChAdOx1 nCoV-19 vaccine induced strong neutralizing antibodies at 28 days after the first dose (geometric mean titer, 132; interquartile range, 20 to 404), which rose further after a second dose (geometric mean titer, 277; interquartile range, 124 to 526) (Figure 2A and Table S5).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seven of the 12 participants (58%) with neutralization activity against B.1.1 had undetectable neutralization activity against the B.1.351 variant, and the remaining 5 showed neutralization that was lower by a factor of 4.1 to 31.5 (Figure 2C).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the six placebo recipients recently infected with SARS-CoV-2, all had detectable neutralization of the B.1.1 variant, whereas neutralization activity against the B.1.351 variant was undetectable in two cases, lower neutralization by a factor of 6.0 to 9.5 was noted in three cases, and no change was seen in one case (Figure 2C).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Strength:plain· not yet calibratedn = 3Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Forty-one of the 42 nasal swab samples (97.6%) were successfully sequenced and classified; 39 (95.1%) cases were caused by the B.1.351 variant and 2 (4.9%; both in the placebo group) by the B.1.1.1 and B.1.144 lineages (Fig. S8).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Vaccine Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, among seropositive participants who had had a nonreactive nucleic acid amplification test before or at randomization, the incidence of mild-to-moderate Covid-19 more than 14 days after the second injection did not differ between placebo (81.9 per 1000 person-years) and vaccine (73.2 per 1000 person-years) recipients; vaccine efficacy was 10.6% (95% CI, −66.4 to 52.2) (Table S6).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Vaccine Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Six of 13 vaccine recipients (46%) without evidence of previous SARS-CoV-2 infection showed no neutralization activity against an RBD triple-mutant pseudovirus (containing K417N, E484K, and N501Y variants), and 11 of the 13 (85%) had no neutralization activity against B.1.351 pseudovirus (Figure 2B).”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Immunogenicity
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The only serious adverse event attributed to the ChAdOx1 nCoV-19 vaccine was a body temperature above 40°C after the first dose; the fever subsided within 24 hours, and no reactogenicity was observed after the second dose.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Results > Safety
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Covid-19 cases were evaluated by at least two physicians who were independent of the trial and were unaware of trial-group assignments.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Efficacy Objectives
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In this multisite, double-blind, randomized, placebo-controlled trial conducted in South Africa, we assessed the safety and efficacy of two standard doses of the ChAdOx1 nCoV-19 vaccine, administered 21 to 35 days apart, as compared with saline (0.9% sodium chloride) placebo.”
- Also stated in: § Methods · plain
“We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Trial Objectives, Participants, and Oversight
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Also stated in: § Methods · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Confidence intervals reported in this article have not been adjusted for multiple comparisons.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Participants 18 to less than 65 years of age were assigned in a 1:1 ratio to receive two doses of vaccine containing 5×1010 viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart.”
- Also stated in: § Trial Procedures · plain
“Trial participants were randomly assigned to receive either a 0.33-to-0.5-ml dose (depending on the lot) of the ChAdOx1 nCoV-19 vaccine or placebo by intramuscular injection on the day of randomization and a second injection 21 to 35 days later.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Methods
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Also stated in: § Trial Procedures · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent data and safety monitoring committee reviewed efficacy and unblinded safety data.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Trial Objectives, Participants, and Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was end-point–driven for the composite of mild, moderate, or severe Covid-19 and required 42 cases to detect a vaccine efficacy of at least 60% (with a lower bound of 0% for the 95% confidence interval), with 80% power.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Testing of neutralizing antibody activity against the original virus and the B.1.351 variant was undertaken before unblinding of trial-group assignments.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Neutralization Assays
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Interim results from South Africa reported a vaccine efficacy of 57% against moderate-to-severe Covid-19 and 89% against severe Covid-19 mainly due to the B.1.351 variant.13”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Discussion
What the sources say
- Not checked yetcites [13] Johnson & Johnson. Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use — first single-shot vaccine in fight against global pandemic. February 27, 2021 (https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial).
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was monitored by an external clinical research organization, which ensured adherence to the protocol.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Trial Objectives, Participants, and Oversight
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Of note, the vaccine efficacy in preventing Covid-19 due to the B.1.351 variant was estimated in a secondary analysis; the trial was powered for the primary objective of a vaccine efficacy of at least 60% in preventing Covid-19 of any severity, irrespective of variants.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Discussion
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Neutralizing activity of the two mRNA vaccines against the B.1.351 variant has also been observed to be lower, by a factor of 8.6 (mRNA-1273 vaccine [Moderna]) or 6.5 (BNT-162b2 vaccine [Pfizer]) on pseudovirus neutralization assay, than activity against the D614G virus, whereas no difference was evident against the N510Y.V1 (B.1.1.7)–like mutant.19,28,29”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Discussion
What the sources say
- Not checked yetcites [19] Wang P, Liu L, Iketani S, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. January 26, 2021 (https://www.biorxiv.org/content/10.1101/2021.01.25.428137v1). preprint. source
- Not checked yetcites [28] Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021 January 29 (Epub ahead of print). 33514629 PMC7971771 source
- Not checked yetcites [29] Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. DOI: 10.1056/NEJMc2102017. PMC7944950 33684280 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The sensitivity of B.1.351 to neutralizing antibodies from convalescent donors infected with the prototype lineage virus, assessed with a spike-pseudovirus neutralization assay, indicated that 48% of serum samples were unable to neutralize B.1.351, with the rest showing a reduction in neutralization titers by a factor of 3 to 86.21”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Abstract > Conclusions
What the sources say
- Not checked yetcites [21] Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 2021 March 2 (Epub ahead of print). 33654292 source
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Injections were prepared and administered by site staff who were aware of participants’ trial-group assignments but were not involved in any other trial procedures. Trial participants and all other trial staff remain unaware of trial-group assignments.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Trial Procedures
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Vaccine efficacy against the B.1.351 variant was a prespecified secondary objective.”
§ Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant > Methods > Efficacy Objectives
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“recent reports suggest that these variants are partially resistant to neutralization by monoclonal antibodies against spike protein, by convalescent plasma and, notably, by sera from participants who have received severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines91,94,95.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [95]
In the citing paper
“Alternatively, if the loss of antibody neutralization abrogates protection even when T cell recognition is maintained, this suggests a primary role for neutralizing antibodies95.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [95]
In the citing paper
“Concerning neutralization of VOCs, recent studies have consistently reported lower neutralizing antibody titers against B.1.351 after vaccination but not against B.1.1.7 (39, 42, 48–59).”
From SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients (2021) · cites this paper as [39]
In the citing paper
“Several studies have now shown that there is reduced vaccine efficacy against mild to moderate disease in countries where B1.351 was dominant (Zhou et al., 2021; Shinde et al., 2021; Madhi et al., 2021, Vaccines and Related Biological Products Advisory Committee, 2021), although protection against severe disease appears to be preserved.”
From Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (2021) · cites this paper as Madhi et al., 2021
In the citing paper
“ChAdOx1-nCoV19 was evaluated in a phase 2 trial (N=2026) in South Africa, in a study population resembling ours with predominantly mild to moderate Covid-19, and reported vaccine efficacy of 22% (95% CI: −50 to 60) overall, and 10% (95% CI: −77 to 55) against the B.1.351 variant, with the latter comprising 95% of cases.25”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [25]
In the citing paper
“Of plasma samples from persons receiving the AZD1222 vaccine, 42% had 3-fold to 10-fold and 54% had >10-fold reduced Beta variant neutralizing activity 104,214,224 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [224]
In the citing paper
“In a phase II trial in South Africa of AZD1222 in which 39 HIV-negative patients became infected with the Beta variant, the estimated vaccine efficacy was just 10% 224 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [224]
In the citing paper
“Neutralizing antibodies are a likely correlate of protection against SARS-CoV-2 infection, as suggested by vaccine efficacy studies, preclinical studies in mice and non-human primates, and data from the early use of convalescent plasma in elderly patients 4,5,10,13,14,18,23 .”
From Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (2021) · cites this paper as [10]
In the citing paper
“In addition, the emergence of new variants with increased transmissibility 8 and reduced sensitivity to vaccine-elicited antibodies 9 , and for which vaccines are less able to prevent infection 10 , has raised fears for vulnerable groups in whom the magnitude and quality of immune responses may be suboptimal.”
From Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (2021) · cites this paper as [10]
In the citing paper
“Initial reports from clinical trials or from breakthrough community infections suggest that current vaccines might be less protective against symptomatic infection with some SARS-CoV-2 variants.5, 6”
From Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis (2022) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Vaccine and placebo recipient counts are reversed
MinorThe abstract assigns 1010 recipients to placebo and 1011 to vaccine, while the Results section assigns 1010 to vaccine and 1011 to placebo.
“1010 and 1011 participants received at least one dose of placebo or vaccine, respectively.”
“Overall, 1010 participants received the vaccine and 1011 received the placebo (Figure 1).”
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Self-citationAntibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Flagged first, then by citations
Research works printed but not linked: 5
- Pfizer. Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. November 9 2020 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against).
- Tegally H Wilkinson E Giovanetti M et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. December 22 2020 (https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1). preprint. · DOI
- Emary KRW Golubchik T Aley PK et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). February 4 2021. preprint.
- National Institute for Communicable Diseases. Dominance of the SARS-CoV-2 501Y.V2 lineage in Gauteng. January 28 2021 (https://www.nicd.ac.za/wp-content/uploads/2021/01/Dominance-of-the-SARS-CoV-2-501Y.V2-lineage-in-Gauteng-South-Africa-1.pdf.) preprint.
- Amnesty International. COVID-19: Oxford/AstraZeneca vaccine a boost for global access but huge inequality remains. November 23 2020 (https://www.amnesty.org/en/latest/news/2020/11/oxford-astrazeneca-vaccine-a-boost-for-global-access-but-huge-inequality-remains).
Cited by
Sorted by citations
Items 501–600 of 989
Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1
Stefanelli, P., Trentini, F., Guzzetta, G., et al. (2021) · medRxiv · doi:10.1101/2021.04.06.21254923 · Cited by 15
Sialubanje, C., Nawa, M., Ng'andu, M., Sumani, E. M., Nkonkomalimba, M., Lyatumba, D. E., Mwale, A., Mpiana, F., Zulu, J. M., Mweempwa, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058028 · Cited by 22
Zamai, L., & Rocchi, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15620 · Cited by 14
ACE2 : S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics
Chitsike, L., Krstenansky, J. L., & Duerksen-Hughes, P. J. (2021) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2021/1828792 · Cited by 15
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Naik, R., Avula, S., Palleti, S. K., Gummadi, J., Ramachandran, R., Chandramohan, D., Dhillon, G. S., Gill, A. S., Paiwal, K., Shaik, B. F., et al. (2023) · Cureus · doi:10.7759/cureus.48046 · Cited by 17
Modelling optimal lockdowns with waning immunity
Goenka, A., Liu, L., & Nguyen, M. (2022) · Economic Theory · doi:10.1007/s00199-022-01468-8 · Cited by 18
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Wang, J., Zhang, Q., Wang, H., & Gong, W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705157 · Cited by 14
COVID-19 transmission and the safety of air travel during the pandemic: a scoping review
Khatib, A. N., McGuinness, S. L., & Wilder‐Smith, A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000771 · Cited by 17
The origins of new SARS-COV-2 variants in immunocompromised individuals
Riddell, A. C., & Cutiño‐Moguel, T. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000794 · Cited by 12
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573647 · Cited by 13
Efficacy and Safety of COVID-19 Vaccines—An Update
Sharma, E., Revinipati, S., Bhandari, S., Thakur, S., Goyal, S., Ghose, A., Bajpai, S., Muhammad, W., & Boussios, S. (2022) · Diseases · doi:10.3390/diseases10040112 · Cited by 17
Deliyannis, G., Gherardin, N. A., Wong, C. Y., Grimley, S. L., Cooney, J. P., Redmond, S. J., Ellenberg, P. C., Davidson, K. C., Mordant, F. L., Smith, T., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104574 · Cited by 16
Cohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 21
Wilkinson, T. M. A., Soyza, A. D., Carroll, M. W., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00249-2023 · Cited by 13
Ma, Q., Lei, B., Chen, R., Liu, B., Lu, W., Jiang, H., Chen, Z., Guo, X., Wang, Y., Zhang, L., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00598-4 · Cited by 14
Covishield vaccine induces robust immune responses in Bangladeshi adults
Bhuiyan, T. R., Akhtar, M., Khaton, F., Rahman, S. I. A., Ferdous, J., Alamgir, A. S. M., Rahman, M., Kawser, Z., Hasan, I., Calderwood, S. B., et al. (2022) · IJID Regions · doi:10.1016/j.ijregi.2022.04.006 · Cited by 10
Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 18
van der Velden, Y. U., Grobben, M., Caniels, T. G., Burger, J. A., Poniman, M., Oomen, M., Rijnstra, E. S.-V., Tejjani, K., Guerra, D., Kempers, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07590-w · Cited by 21
Ibrahim, L. F., Tham, D., Chong, V., Corden, M., Craig, S. S., Buntine, P., Jani, S., Zhang, M., George, S., Kochar, A., et al. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51207 · Cited by 36
SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
Khamees, A., Bani-Issa, J., Zoubi, M. S. A., Qasem, T., Alarjah, M. I. A., Alawadin, S. A., Al‐Shami, K., Hussein, F. H., Hussein, E. I., Bashayreh, I. H., et al. (2022) · Pathogens · doi:10.3390/pathogens11020275 · Cited by 19
Duchêne, S., Featherstone, L. A., de Blasio, B. F., Holmes, E. C., Bohlin, J., & Pettersson, J. H. ‐. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.44.2001996 · Cited by 18
Rocha, V. P. C., Quadros, H. C., Fernandes, A. M. S., Gonçalves, L. P., Badaró, R. J. D. S., Soares, M. B. P., & Machado, B. A. S. (2023) · Viruses · doi:10.3390/v15071504 · Cited by 13
Kibria, K. M. K., Faruque, M. O., Islam, M. S. B., Ullah, H., Mahmud, S., Miah, M., & Saleh, A. A. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11988-x · Cited by 16
Hitchings, M., Ranzani, O., Dorión, M., et al. (2021) · medRxiv · doi:10.1101/2021.07.19.21260802 · Cited by 19
Mohraz, M., Vahdat, K., Ghamari, S., Abbasi‐Kangevari, M., Ghasemi, E., Ghabdian, Y., Rezaei, N., Pouya, M. A., Abdoli, A., Malekpour, M., et al. (2023) · BMJ · doi:10.1136/bmj-2023-070464 · Cited by 16
Walters, J. N., Schouest, B., Patel, A. R., Reuschel, E. L., Schultheis, K., Parzych, E. M., Maricic, I., Gary, E. N., Purwar, M., Andrade, V. M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.060 · Cited by 14
Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease
Hussman, J. P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.637642 · Cited by 11
The Potential Beneficial Effects of Vaccination on Antigenically Evolving Pathogens
Wen, F. T., Malani, A., & Cobey, S. E. (2021) · The American Naturalist · doi:10.1086/717410 · Cited by 14
Chong, Z. X., Liew, W.-P.-P., Ong, H. K., Yong, C. Y., Shit, C. S., Ho, W. Y., Ng, S., & Yeap, S. K. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153565 · Cited by 13
Advancements in Testing Strategies for COVID-19
Asghar, R., Rasheed, M., Hassan, J. U., Rafique, M., Khan, M., & Deng, Y. (2022) · Biosensors · doi:10.3390/bios12060410 · Cited by 17
Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes
Akbay, B., Abidi, S. H., Ibrahim, M. A. A., Mukhatayev, Z., & Ali, S. (2021) · Vaccines · doi:10.3390/vaccines9070702 · Cited by 12
Dumache, R., Enache, A., Macasoi, I. G., Dehelean, C. A., Dumitrascu, V. C., Mihailescu, A., Popescu, R., Vlad, M., Vlad, C. S., & Mureşan, C. O. (2022) · Pathogens · doi:10.3390/pathogens11050516 · Cited by 17
Nolan, T. M., Deliyannis, G., Griffith, M., Braat, S., Allen, L. F., Audsley, J., Chung, A. W., Ciula, M., Gherardin, N. A., Giles, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104878 · Cited by 16
Immune Responses Following the First Dose of the Sputnik V (Gam-COVID-Vac)
Jeewandara, C., Fernando, S., Pushpakumara, P. D., Ramu, S. T., Kamaladasa, A., Gunasekara, B., Aberathna, I. S., Kuruppu, H., Ranasinghe, T., Dayarathne, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-022-05788-6 · Cited by 12
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19
Pan, J., Zhu, W., Tian, J., Liu, Z., Xu, A., Yao, Y., & Wang, W. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00960-6 · Cited by 14
Brandys, P., Montagutelli, X., Merenkova, I., Barut, G. T., Thiel, V., Schork, N. J., Trüeb, B. S., Conquet, L., Deng, A., Antanasijevic, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912898 · Cited by 11
Rapid and Flexible RT-qPCR Surveillance Platforms To Detect SARS-CoV-2 Mutations
Spieß, K., Gunalan, V., Marving, E. L., Nielsen, S. H., Jørgensen, M. G. P., Fomsgaard, A. S., Nielsen, L., Alfaro‐Núñez, A., Karst, S. M., Mortensen, S., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03591-22 · Cited by 24
Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
Assaid, N., Arich, S., Charoute, H., Akarid, K., Ezzikouri, S., Maaroufi, A., & Sarih, M. (2022) · Vaccines · doi:10.3390/vaccines10030465 · Cited by 12
Speer, C., Morath, C. P., Töllner, M., Buylaert, M., Göth, D., Nußhag, C., Kälble, F., Schaier, M., Grenz, J., Kreysing, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.721286 · Cited by 13
Bochnia-Bueno, L., de Almeida, S. M., Raboni, S. M., Adamóski, D., Amadeu, L. L. M., Carstensen, S., & Nogueira, M. B. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115597 · Cited by 24
Nwabufo, C. K., Hoque, M. T., Yip, L., Khara, M., Mubareka, S., Pollanen, M. S., & Bendayan, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1124693 · Cited by 13
Vimalanathan, S., Shehata, M., Kannan, S., Delbue, S., Dolci, M., Pariani, E., D’Alessandro, S., & Pleschka, S. (2022) · Microorganisms · doi:10.3390/microorganisms10112145 · Cited by 24
Wang, W., Chen, Y., Su, W., Liu, Y., Shen, W., Chang, W., Huang, S., Lin, C., Wang, Y., Yang, C., et al. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14354 · Cited by 15
Comprehensive Understanding and Field Application of COVID-19 Vaccine
Choi, W. S. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.3.155 · Cited by 11
Neerukonda, S., Vassell, R., Lusvarghi, S., et al. (2021) · bioRxiv · doi:10.1101/2021.11.05.467523 · Cited by 12
Vogrig, M., Berger, A.-E., Bourlet, T., Waeckel, L., Haccourt, A., Chanavat, A. H., Hupin, D., Roche, F., Botelho-Nevers, É., Pozzetto, B., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01354-x · Cited by 13
Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19
Tai, W., Chow, M. Y. T., Chang, R. Y. K., Tang, P., Gonda, I., MacArthur, R. B., Chan, H., & Kwok, P. C. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081260 · Cited by 12
An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · Viruses · doi:10.3390/v13102009 · Cited by 10
Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., Juengling, J., Junker, D., Hernández, P., Gornyk, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828053 · Cited by 12
Volkan, E. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00353-4 · Cited by 12
Kostaki, E. G., Tseti, I. K., Tsiodras, S., Pavlakis, G. N., Sfikakis, P. P., & Paraskevis, D. N. (2021) · Life · doi:10.3390/life11050375 · Cited by 13
Bai, A. D., Jiang, Y., Nguyen, D. L., Lo, C. K. L., Stefanova, I. Z., Guo, K., Wang, F., Zhang, C., Sayeau, K., Garg, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53301 · Cited by 13
Riou, C., Bhiman, J. N., Ganga, Y., Sawry, S., Ayres, F., Baguma, R., Balla, S. R., Benede, N., Bernstein, M. P., Besethi, A. S., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002703 · Cited by 16
Self-citationNext-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein
Bonam, S. R., & Hu, H. (2023) · Zoonoses · doi:10.15212/zoonoses-2023-0003 · Cited by 12
Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman PrimatesPreprint
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M. J., Foulds, K. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.21.445189 · Cited by 11
Maaske, J., Sproule, S., Falsey, A. R., Sobieszczyk, M. E., Luetkemeyer, A. F., Paulsen, G. C., Riddler, S. A., Robb, M. L., Rolle, C.-P., Sha, B. E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062067 · Cited by 15
Self-citationSARS-CoV-2: Vaccinology and Emerging therapeutics; Challenges and Future Developments
Adesokan, A. M., Obeid, M. A., & Lawal, A. F. (2022) · Therapeutic Delivery · doi:10.4155/tde-2021-0075 · Cited by 12
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Liu, Y., Dai, L., Feng, X., Gao, R., Zhang, N., Wang, B., Han, J.-B., Zou, Q., Guo, X., Zhu, H., et al. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00054-z · Cited by 11
Peter, A. S., Grüner, E., Socher, E., Fraedrich, K., Richel, E., Mueller-Schmucker, S. M., Cordsmeier, A., Ensser, A., Sticht, H., & Überla, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158177 · Cited by 13
Wang, B., Xu, J., Wu, S., Zhang, Z., Zhao, Z., Zhang, J., Fu, L. L., Zai, X., Wang, Y., Zhang, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01065-0 · Cited by 11
Yang, B., Huang, X., Gao, H., Leung, N., Tsang, T. K., & Cowling, B. J. (2022) · BMC Medicine · doi:10.1186/s12916-022-02600-0 · Cited by 14
Zhang, J., He, L., Huang, R., et al. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08504-3 · Cited by 11
Zhao, L., Lybrand, T., Gilbert, P., et al. (2021) · bioRxiv · doi:10.1101/2021.06.15.448495 · Cited by 11
Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response
Ludwig, H., Miguel, J. F. S., Munshi, N. C., Sonneveld, P., Mateos, M., Moreau, P., & Terpos, E. (2021) · American Journal of Hematology · doi:10.1002/ajh.26263 · Cited by 11
Success of nano-vaccines against COVID-19: a transformation in nanomedicine
Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148659 · Cited by 11
Immune response variables and viral mutations impact on COVID-19 reinfection and relapse
Sanaie, S., Golipour, E., Shamekh, A., Sadaie, M. R., Mahmoodpoor, A., & Yousefi, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108108 · Cited by 12
SARS-CoV-2 spike therapeutic antibodies in the age of variants
Baum, A., & Kyratsous, C. A. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210198 · Cited by 12
COVID-19 Risk Assessment for the Tokyo Olympic Games
Zhu, W., Feng, J., Li, C., Wang, H., Zhong, Y., Zhou, L. J., Zhang, X., & Zhang, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.730611 · Cited by 14
Recent update on future therapeutic strategies for COVID-19 vaccination with omicron variant
Ellakwa, D. E., Elsheikh-Hassan, A. F., Ellakwa, T. E., & Abdelmalek, M. A. (2024) · Human Gene · doi:10.1016/j.humgen.2024.201281 · Cited by 11
Dubé, C., Paris‐Robidas, S., Andreani, G., Gutzeit, C., D’Aoust, M., Ward, B. J., & Trépanier, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.046 · Cited by 11
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 13
Sherman, A. C., Desjardins, M., & Baden, L. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.008 · Cited by 11
COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants
Wussow, F., Kha, M., Faircloth, K., Nguyen, V. H., Iniguez, A., Martinez, J., Park, Y., Nguyen, J., Kar, S., Andersen, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104457 · Cited by 12
O’Donnell, K. L., Gourdine, T., Fletcher, P., Shifflett, K., Furuyama, W., Clancy, C. S., & Marzi, A. (2022) · Vaccines · doi:10.3390/vaccines10030435 · Cited by 8
COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10
ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies
Fielding, C., Sabberwal, P., Williamson, J., et al. (2021) · bioRxiv · doi:10.1101/2021.04.06.438630 · Cited by 10
Dupont, L., Snell, L., Graham, C., et al. (2021) · medRxiv · doi:10.1101/2021.06.07.21258351 · Cited by 10
Shalash, A. O., Azuar, A., Madge, H. Y. R., Modhiran, N., Amarilla, A. A., Liang, B., Khromykh, A. A., Hussein, W. M., Chappell, K. J., Watterson, D., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040856 · Cited by 13
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N. A., Allen, M., Antony, J., Bhate, A. S., Beresnev, T. H., Bonaparte, M. I., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102168 · Cited by 11
Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors
Razafimahatratra, S. L., Ndiaye, M. D., Rasoloharimanana, L. T., Dussart, P., Sahondranirina, P. H., Randriamanantany, Z. A., & Schoenhals, M. J. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00361-2 · Cited by 14
Clemens, S. A. C., Milan, E. P., Sprinz, E., Neto, J. C., Pacciarini, F., Li, P., Chen, H., Smolenov, I. V., Pollard, A. J., & Clemens, R. L. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac418 · Cited by 10
Self-citationMendoza-Salazar, I., Gómez-Castellano, K., González‐González, E., Gamboa-Suasnavart, R. A., Rodríguez-Luna, S. D., Santiago-Casas, G., Cortés-Paniagua, M. I., Pérez‐Tapia, S. M., & Almagro, J. C. (2022) · Antibodies · doi:10.3390/antib11010013 · Cited by 13
RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge
Wong, T. Y., Russ, B. P., Lee, K. S., Miller, O. A., Kang, J. H., Cooper, M., Winters, M. T., Rodriguez‐Aponte, S. A., Dalvie, N. C., Johnston, R. S., et al. (2022) · mSphere · doi:10.1128/msphere.00243-22 · Cited by 12
Warne, B., Enright, J. A., Metaxaki, M., Fuller, S., Samworth, R. J., Weale, G., Holgate, J., Samtani, V., Brierley, C., Aggarwal, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-520626/v1 · Cited by 9
Hu, L., Xu, Y., Wu, L., Feng, J., Zhang, L., Tang, Y., Zhao, X., Mai, R., Chen, L., Mei, L., et al. (2022) · Viruses · doi:10.3390/v14050854 · Cited by 11
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12
Sonabend, R., Whittles, L., Imai, N., et al. (2021) · medRxiv · doi:10.1101/2021.08.17.21262164 · Cited by 10
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsPreprint
Cho, H., Gonzales-Wartz, K. K., Huang, D.-L., Yuan, M., Peterson, M., Liang, J. Y., Beutler, N., Torres, J., Cong, Y., Postnikova, E., et al. (2021) · bioRxiv · doi:10.1101/2021.04.01.437942 · Cited by 10
Chang, A. Y., Aaby, P., Avidan, M. S., Benn, C. S., Bertozzi, S. M., Blatt, L., Chumakov, K., Khader, S. A., Kottilil, S., Nekkar, M., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.967920 · Cited by 10
Eslami, S., Glassy, M. C., & Ghafouri‐Fard, S. (2021) · Gene · doi:10.1016/j.gene.2021.146113 · Cited by 12
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina, N. L., Sperotto, M. G., Puga, M. A. M., da Silva, P. V., de Oliveira, R. D., Moore, C. L., Pittet, L. F., Jamieson, T., Dalcolmo, M. P., dos Santos, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172851 · Cited by 10
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Mahrokhian, S. H., Tostanoski, L. H., Jacob-Dolan, C., Zahn, R. C., Wegmann, F., McMahan, K., Yu, J., Gebre, M. S., Bondzie, E. A., Wan, H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00454-4 · Cited by 10
Viskupič, F., Wiltse, D. L., & Meyer, B. A. (2022) · The Social Science Journal · doi:10.1080/03623319.2022.2049557 · Cited by 14
Early super-spreader events are a likely determinant of novel SARS-CoV-2 variant predominance
Goyal, A., Reeves, D., & Schiffer, J. (2021) · medRxiv · doi:10.1101/2021.03.23.21254185 · Cited by 10
Yousaf, N., Jabeen, Y., Imran, M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2189478 · Cited by 10
SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
Natarelli, L., Virgili, F., & Weber, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212243 · Cited by 12
Lee, B. E., Sikora, C. A., Faulder, D., Risling, E., Little, L. A., Qiu, Y., Gao, T., Bulat, R., Craik, S. A., Hrudey, S. E., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052282 · Cited by 17
Terada, M., Kondo, N., Wanifuchi‐Endo, Y., Fujita, T., Asano, T., Hisada, T., Uemoto, Y., Kato, A., Yamanaka, N., Sugiura, H., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06693-2 · Cited by 11
Egia‐Mendikute, L., Bosch, A., Prieto‐Fernández, E., Vila-Vecilla, L., Zanetti, S. R., Lee, S. Y., Jiménez-Lasheras, B., Río, A. G.-D., Antoñana-Vildosola, A., de Blas, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1014309 · Cited by 9
Metadata
- Authors
- Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha, S., Bhiman, J. N., Bhorat, A. E., du Plessis, J., Esmail, A., Groenewald, M., Horne, E., Hwa, S.-H., Jose, A., Lambe, T., Laubscher, M., Malahleha, M., Masenya, M., Masilela, M., McKenzie, S., Molapo, K., Moultrie, A., Oelofse, S., Patel, F., Pillay, S., Rhead, S., Rodel, H., Rossouw, L., Taoushanis, C., Tegally, H., Thombrayil, A., van Eck, S., Wibmer, C. K., Durham, N. M., Kelly, E. J., Villafana, T. L., Gilbert, S., Pollard, A. J., de Oliveira, T., Moore, P. L., Sigal, A., & Izu, A.
- Affiliations
- South African Medical Research Council (ZA)
- University of the Witwatersrand (ZA)
- University of Oxford (GB)
- Setshaba Research Centre (ZA)
- University of Cape Town (ZA)
- Stellenbosch University (ZA)
- Soweto CTC (ZA)
- National Health Laboratory Service (ZA)
- Africa Health Research Institute (ZA)
- Max Planck Institute for Infection Biology (DE)
- AstraZeneca (United Kingdom) (GB)
- From the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (S.A.M., V.B., A.L.K., G.K., S.B., J.P., A.J., M.L., S.M., A.M., C.T., A.T., A.I.), African Leadership in Vaccinology Expertise (C.L.C.), Wits Reproductive Health and HIV Institute (L.F., E.H., M. Masenya, F.P., S.E.), the Antibody Immunity Research Unit, School of Pathology (J.N.B., C.K.W., P.L.M.), and the Perinatal HIV Research Unit (C.B.), Faculty of Health Sciences, and the Department of Science and Innovation/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases Unit (S.A.M., V.B., A.L.K., G.K., S.B., A.I.), University of the Witwatersrand, and the National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS) (J.N.B., C.K.W., P.L.M.), Johannesburg, Setshaba Research Centre, Tshwane (S.D.P., K.A., M. Malahleha, M. Masilela, K.M.), the Division of Pulmonology, Groote Schuur Hospital and the University of Cape Town ...
- Corresponding author
- Madhi, Shabir A.
- ORCID
- Madhi, Shabir A.
- Baillie, Vicky
- Cutland, Clare L.
- Voysey, Merryn
- Koen, Anthonet L.
- Fairlie, Lee
- Dheda, Keertan
- Barnabas, Shaun L.
- Bhorat, Qasim E.
- Briner, Carmen
- Kwatra, Gaurav
- Ahmed, Khatija
- Aley, Parvinder
- Bhiman, Jinal N.
- Bhorat, As’ad E.
- Esmail, Aliasgar
- Horne, Elizea
- Hwa, Shi-Hsia
- Lambe, Teresa
- Laubscher, Matt
- Malahleha, Mookho
- Masenya, Masebole
- Moultrie, Andrew
- Oelofse, Suzette
- Patel, Faeezah
- Pillay, Sureshnee
- Rhead, Sarah
- Rodel, Hylton
- Taoushanis, Carol
- Tegally, Houriiyah
- Wibmer, Constantinos K.
- Durham, Nicholas M.
- Kelly, Elizabeth J.
- Villafana, Tonya L.
- Gilbert, Sarah
- Pollard, Andrew J.
- Moore, Penny L.
- Sigal, Alex
- Izu, Alane
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-20
- Volume
- 384
- Issue
- 20
- Pages
- 1885-1898
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7993410
- OpenAlex
- W3139533040
- Cited by
- 1,257
- References
- 23
- Citations by year
- 2026: 9 · 2025: 33 · 2024: 64 · 2023: 135 · 2022: 413 · 2021: 600
- FWCI
- 96.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Funders
- Bill and Melinda Gates Foundation (INV-017710)
- South African Medical Research Council (96167)
- U.K. Research and Innovation (MC_PC_19055)
- UK National Institute for Health Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccine efficacy, B.1.351 variant, SARS-CoV-2 variants of concern, neutralizing antibodies, pseudovirus neutralization, symptomatic COVID-19, vaccine safety, adenovirus vector vaccine
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Serological Testing, ChAdOx1 nCoV-19, Adenoviridae, Adolescent, Adult, Double-Blind Method, Humans, Middle Aged, South Africa, T-Lymphocytes, Treatment Failure, Young Adult, Antibodies, Neutralizing, Vaccine Potency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
